CN119698286A - 用于治疗眼部疾病的补体因子i给药方案 - Google Patents

用于治疗眼部疾病的补体因子i给药方案 Download PDF

Info

Publication number
CN119698286A
CN119698286A CN202380045885.4A CN202380045885A CN119698286A CN 119698286 A CN119698286 A CN 119698286A CN 202380045885 A CN202380045885 A CN 202380045885A CN 119698286 A CN119698286 A CN 119698286A
Authority
CN
China
Prior art keywords
per eye
cfi
weeks
seq
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380045885.4A
Other languages
English (en)
Chinese (zh)
Inventor
G·E·布鲁斯
N·勒蒙
T·努森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN119698286A publication Critical patent/CN119698286A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
CN202380045885.4A 2022-05-04 2023-05-04 用于治疗眼部疾病的补体因子i给药方案 Pending CN119698286A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263338392P 2022-05-04 2022-05-04
US63/338,392 2022-05-04
PCT/US2023/066620 WO2023215840A1 (en) 2022-05-04 2023-05-04 Complement factor i dosing regimens for treating ocular diseases

Publications (1)

Publication Number Publication Date
CN119698286A true CN119698286A (zh) 2025-03-25

Family

ID=86760162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380045885.4A Pending CN119698286A (zh) 2022-05-04 2023-05-04 用于治疗眼部疾病的补体因子i给药方案

Country Status (10)

Country Link
US (1) US20250177482A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518881A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515091A (cg-RX-API-DMAC7.html)
KR (1) KR20250008764A (cg-RX-API-DMAC7.html)
CN (1) CN119698286A (cg-RX-API-DMAC7.html)
AU (1) AU2023265150A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251504A1 (cg-RX-API-DMAC7.html)
IL (1) IL316772A (cg-RX-API-DMAC7.html)
TW (1) TW202400627A (cg-RX-API-DMAC7.html)
WO (1) WO2023215840A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117551A1 (en) * 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
WO2021257480A2 (en) * 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods

Also Published As

Publication number Publication date
KR20250008764A (ko) 2025-01-15
JP2025515091A (ja) 2025-05-13
AU2023265150A1 (en) 2024-11-14
CA3251504A1 (en) 2023-11-09
WO2023215840A1 (en) 2023-11-09
EP4518881A1 (en) 2025-03-12
IL316772A (en) 2025-01-01
US20250177482A1 (en) 2025-06-05
TW202400627A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
Duh et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth
US12116606B2 (en) Complement factor I-related compositions and methods
JP2002523377A (ja) 粘液過剰分泌の治療のための組換えボツリヌス菌毒素
US12559540B2 (en) ApoM-Fc fusion proteins and uses thereof
US7223726B2 (en) Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
JP2001520206A (ja) 上皮細胞標的化結合体としてのj鎖およびアナログ
JPS62190084A (ja) ミュレル管抑制物質の活性を示すポリペプチドをコードするdna,組換dnaおよび形質転換宿主
JP7675816B2 (ja) 持効型神経成長因子ポリペプチド及びその用途
CN105829542A (zh) 改进的重组多肽生产方法
CN112384236A (zh) 用于治疗微血管血栓形成的靶向溶栓
CN1051934A (zh) 在真核细胞中表达神经生长因子的基因构建物的制备方法
US5359033A (en) Cleaved dimers of mullerian inhibiting substance-like polypeptides
US20250011379A1 (en) Complement factor i-related compositions and methods
CN120189491A (zh) 用于治疗或预防眼科病症的药剂
JPS63102699A (ja) 新規なdafの製造のための核酸
KR102187751B1 (ko) 눈 잔류가 증가된 안과학용 융합 단백질
CN101914161A (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
US20250177482A1 (en) Complement factor i dosing regimens for treating ocular diseases
TW202602913A (zh) 包含阿柏西普和其變體的組合物以及相關方法和應用
CN116675777A (zh) 包含补体抑制结构域的多特异性配体结合分子及其用途
US11034946B2 (en) Glycosylation independent proteins
US20040192589A1 (en) Production of high molecular mass lectins
US20220168434A1 (en) Application of transthyretin in entering eye and preparing drop
CN116635528A (zh) 补体因子i相关组合物和方法
CN121693326A (zh) 包含透明质酸酶多肽和药物的用于皮下注射的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination